Jade Biosciences, Inc. (JBIO)
Nasdaq · Healthcare · Biotechnology
$14.07−0.35%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $895M
- 52-week range
- $8.36 – $28.00
- 52-week change
- +54.49%
- EPS (trailing)
- −$1.92
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$127M
- Diluted EPS
- −$3.19
- Free cash flow
- −$94.9M
From the company’s annual report on SEC EDGAR.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Headquarters: Waltham, United States · 55 employees · jadebiosciences.com